Accelerate Enterprise Sales
Focus on repeatable installs in reference labs; formal ROI calculators are still missing but essential for scaling.
Platform-as-a-Service
Monetise Virchow APIs broadly; pathologist UX must remain friction-less to avoid workflow backlash.
Capital Strategy
At current burn, a pre-2027 IPO or strategic exit (Philips, Microsoft, or Roche Diagnostics) is plausible if revenue inflects.
Risk Watch-list
FDA's forthcoming "Predetermined Change Control Plan" guidance could force re-submission of adaptive models, impacting margin.